The Bioscan 19(2) S2: 88-92, 2024 www.thebioscan.com
AN INTERNATIONAL QUARTERLY JOURNAL OF LIFE SCIENCES

The Multifaceted Biological Activities of Hydantoin Derivatives: From Antimicrobial to Anticancer Agents

Bhadreshkumar. R. Sudani

Department of Chemical Engineering, Government Engineering College, Valsad.

Address for Correspondence: Department of Chemical Engineering, Government Engineering College, Valsad, Gujarat, India. 396001.

Email: brsudani@gmail.com

DOI: https://doi.org/10.63001/tbs.2024.v19.i02.S2.pp88-92

KEYWORDS
Hydantoin derivatives, antimicrobial activity, anticancer agents, pharmacological properties, structure-activity relationships (SAR)
Received on:
05-04-2024
Accepted on:
19-07-2024
Published on
23-07-2024
Corresponding author

ABSTRACT

Hydantoin derivatives, a versatile class of heterocyclic compounds, have garnered significant attention in recent years due to their diverse biological activities. These derivatives exhibit a wide range of pharmacological properties, making them valuable candidates in the development of therapeutic agents. This review highlights the multifaceted biological activities of Hydantoin derivatives, with a focus on their antimicrobial and anticancer properties. The antimicrobial efficacy of these compounds encompasses activity against various bacterial, fungal, and viral pathogens, presenting them as potential alternatives to conventional antibiotics. Additionally, Hydantoin derivatives have shown promising anticancer activities by inducing apoptosis, inhibiting cell proliferation, and interfering with various cellular signaling pathways. The structural modifications of these derivatives play a crucial role in enhancing their biological activities, providing insights into structure-activity relationships. Moreover, their potential to overcome drug resistance and reduce side effects associated with traditional therapies underscores their therapeutic significance. This review aims to provide a comprehensive overview of the recent advancements in the biological applications of Hydantoin derivatives, emphasizing their role as promising candidates for future drug development in antimicrobial and anticancer therapy. Further research and clinical studies are warranted to fully explore their therapeutic potential and translate these findings into clinical practice.

INTRODUCTION

A. Overview of Hydantoin Derivatives

Hydantoin derivatives, also known as Imidazolidine-2,4-diones, are a class of heterocyclic compounds that have gained significant attention in medicinal chemistry. These compounds feature a five-membered ring with two nitrogen atoms and two carbonyl groups at the 2 and 4 positions, respectively, allowing for various substitutions at different ring positions and leading to a wide array of derivatives with diverse chemical and biological properties (Hamama et al., 2022). Initially, hydantoins were recognized for their anticonvulsant activity, with phenytoin being one of the most well-known drugs from this class (V Krivoshein, 2016). Over time, extensive research has revealed that imidazolidine-2,4-dione derivatives possess numerous other pharmacological activities, making them valuable scaffolds in drug discovery and development (Sudani and Desai, 2019, Borisa & others, 2015).

B. Significance of Their Biological Activities

The biological activities of imidazolidine-2,4-dione derivatives are significant due to their broad spectrum and potent effects. These compounds have demonstrated efficacy in various therapeutic areas, including antimicrobial, anticancer, anti-inflammatory, and antiviral applications. Their antimicrobial properties are particularly noteworthy, as they have shown activity against a wide range of bacterial and fungal pathogens, making them potential candidates for developing new antibiotics in the face of rising antibiotic resistance (Swain, & Mohanty, 2019). Additionally, several imidazolidine-2,4-dione derivatives have exhibited potent anticancer activities by inducing apoptosis and inhibiting tumor cell proliferation, positioning them as promising leads in cancer therapy (Sharma et al., 2021). The versatility of these compounds is further underscored by their ability to modulate multiple biological targets, which can lead to the development of multifunctional therapeutic agents (Cho, 2019).

C. Objectives and Scope of the Paper

The primary objective of this paper is to provide a comprehensive review of the multifaceted biological activities of imidazolidine-2,4-dione derivatives, with a particular focus on their antimicrobial and anticancer properties. By examining the latest research and advancements in this field, we aim to highlight the therapeutic potential of these compounds and their relevance in modern medicinal chemistry. The scope of the paper includes an exploration of the chemical structure and properties of imidazolidine-2,4-dione derivatives, an in-depth analysis of their antimicrobial and anticancer activities, and a discussion on the structure-activity relationships (SAR) that influence their biological functions. Furthermore, we will address the challenges and opportunities in overcoming drug resistance and consider the

future directions for clinical applications and research in this area. This review seeks to consolidate current knowledge and stimulate further investigation into the development of imidazolidine-2,4-dione derivatives as versatile therapeutic agents.

II. Chemical Structure and Properties

A. Basic Chemical Structure of Imidazolidine-2,4-dione

Imidazolidine-2,4-dione, commonly known as hydantoin, consists of a five-membered ring structure with two nitrogen atoms and two carbonyl groups at the 2 and 4 positions, respectively. This unique arrangement imparts significant stability and potential for various chemical modifications. The basic structure can be represented as follows:



Figure 1. Basic structure of imidazolidine-2,4-dione.

B. Structural Variations and Modifications

The versatility of the imidazolidine-2,4-dione scaffold allows for numerous substitutions at various positions on the ring, leading to a wide range of derivatives with diverse biological activities. Structural modifications primarily occur at the N1, N3 and C5 positions, allowing for the introduction of different functional groups such as alkyl, aryl, and acyl groups. These modifications can significantly alter the compound's physicochemical and biological properties (Sevvanthi et al., 2017).

For example:

- Substitution at the N1 position can yield N-alkyl or N-aryl derivatives.
- Modifications at the C5 position often involve the introduction of various side chains or ring systems, which can enhance biological activity.



Figure 2. Examples of some structural derivatives of imidazolidine-2,4-dione.

C. Chemical Properties and Synthesis Methods

Hydantoin derivatives exhibit a range of chemical properties that make them suitable for diverse pharmacological applications. They are generally stable under physiological conditions and possess favorable solubility profiles, which are critical for drug development (Toumi et al., 2023).

The synthesis of imidazolidine-2,4-dione derivatives typically involves cyclization reactions of amino acids or their derivatives. One common method is the Bucherer-Bergs reaction, which involves the reaction of potassium cyanate with amino acids to form the hydantoin ring (Griffith & Wolf, 1997). Another widely used method is the Ugi reaction, which allows for the rapid and efficient synthesis of diverse hydantoin derivatives by combining isocyanides, aldehydes, amines, and carboxylic acids (Marques et al., 2022). The general synthetic route can be depicted as following figure-3:



Figure 3. General synthetic route to imidazolidine-2,4-dione derivatives.

E.g. P. P. Mistry and V. A. Desai (2012) studied the synthesis of 3,5-disubstituted imidazolidine-2,4-dione via Mannich reaction between various secondary amines and hydantoin derivatives. They prepared 5-alkyl, 5-aryl hydantoin derivatives from aryl ketone and KCN with ammonium carbonate by Bucherer-Bergs reaction mechanism and than merged them with secondary amines to get some bioactive hydantoin derivatives. (Figure-4)



Figure 4: Synthetic route by P. P. Mistry and V. A. Desai (2012)

III. Antimicrobial Activities

A. General Antimicrobial Properties

Imidazolidine-2,4-dione derivatives, commonly known as hydantoins, are recognized for their broad-spectrum antimicrobial properties. These compounds exhibit significant activity against various pathogens, including bacteria, fungi, and viruses. Their antimicrobial efficacy is largely due to their ability to interfere with vital biological processes within microbial cells, ultimately leading to inhibition of growth or cell death (Nyaki et al., 2023).

B. Activity Against Bacterial Pathogens

Gram-positive Bacteria: Hydantoin derivatives exhibit potent activity against Gram-positive bacteria such as *Staphylococcus aureus*, *Bacillus subtilis*, and *Streptococcus pneumoniae*. The mechanisms often involve disruption of cell wall synthesis or inhibition of protein synthesis, which results in bacterial cell death. For instance, N-substituted hydantoin derivatives have demonstrated strong bactericidal activity against methicillin-resistant *Staphylococcus aureus* (MRSA) (Mondino et al. 2022) (Sudani, 2016).



Figure 5. Structural examples of hydantoin derivatives effective against Gram-positive bacteria. **Gram-negative Bacteria:** Hydantoin derivatives are also effective against Gram-negative bacteria, including *Escherichia coli*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. These compounds can permeabilize the

bacterial outer membrane or inhibit critical enzymes involved in bacterial metabolism. Research indicates that certain hydantoin derivatives significantly reduce the viability of multidrug-resistant Gram-negative bacterial strains (Su M. Xia et al., 2017).



Figure 2. Structural examples of hydantoin derivatives effective against Gram-negative bacteria.

C. Activity Against Fungal Pathogens

Hydantoin derivatives display strong antifungal activities against a variety of fungal pathogens, including *Candida albicans*, *Aspergillus niger*, and *Cryptococcus neoformans*. These compounds typically inhibit ergosterol synthesis or disrupt fungal cell membrane integrity, leading to cell lysis. Wang et al. (2018) demonstrated that hydantoin-based antifungal agents effectively inhibit the growth of resistant fungal strains.



Figure 3. Structural examples of hydantoin derivatives effective against fungal pathogens.

D. Antiviral Properties

The antiviral potential of hydantoin derivatives is increasingly recognized. These compounds have shown activity against various viruses, including influenza virus, herpes simplex virus (HSV), and human immunodeficiency virus (HIV). The antiviral mechanisms often involve inhibition of viral replication or disruption of viral protein function. For example, Mousavi et al. (2019) reported that certain hydantoin derivatives inhibit HSV replication by targeting viral DNA polymerase.



Figure 4. Structural examples of hydantoin derivatives effective pathogens.

1. **Mechanisms of Antimicrobial Action** The antimicrobial action of hydantoin derivatives involves several mechanisms, including:
2. **Inhibition of Cell Wall Synthesis**: Hydantoins can interfere with the synthesis of bacterial cell walls, leading to cell lysis.
3. **Disruption of Protein Synthesis**: By binding to bacterial ribosomes, hydantoins can inhibit protein synthesis, which is essential for bacterial growth and reproduction.
1. **Membrane Permeabilization**: Some derivatives disrupt the integrity of microbial cell membranes, causing leakage of cellular contents and cell death.
2. **Enzyme Inhibition**: Hydantoins can inhibit critical enzymes required for microbial metabolism, thereby hindering growth and survival.
3. **DNA/RNA Synthesis Interference**: Certain derivatives can inhibit nucleic acid synthesis, preventing viral replication and bacterial proliferation (Bhattacharjee, 2022).

IV. Anticancer Activities:

A. General Anticancer Properties: Imidazolidine-2,4-dione derivatives, widely known as hydantoins, have garnered significant attention for their potential anticancer properties. These compounds exhibit a range of activities against various cancer cell lines, primarily through mechanisms that disrupt critical cellular processes necessary for cancer cell survival and proliferation. The structural versatility of hydantoins allows for the design of derivatives with enhanced specificity and potency against cancer cells (Upadhyay et al., 2020).

B. Mechanisms of Anticancer Action:

Induction of Apoptosis: One of the primary mechanisms by which hydantoin derivatives exert their anticancer effects is through the induction of apoptosis, or programmed cell death. Apoptosis is a controlled process that eliminates damaged or unwanted cells. Hydantoins can trigger apoptosis by activating pro-apoptotic proteins and pathways, leading to cell death. For example, certain hydantoin derivatives have been shown to activate caspases, a family of proteases essential for the execution of apoptosis (Singh et al., 2019).

Inhibition of Cell Proliferation: Hydantoin derivatives can also inhibit the proliferation of cancer cells. This is achieved by interfering with the cell cycle, preventing cells from progressing through the stages necessary for division and growth. By targeting key regulatory proteins and enzymes involved in cell cycle progression, hydantoins can effectively halt the proliferation of cancer cells (Kavitha et al., 2009).

Disruption of Cellular Signalling Pathways: Another critical mechanism is the disruption of cellular signalling pathways that are often deregulated in cancer. Hydantoin derivatives can inhibit signalling pathways such as the PI3K/Akt/mTOR pathway, which is crucial for cell growth and survival. By targeting these pathways, hydantoins can reduce cancer cell viability and induce cell death (Sunil & Kamath, 2017).

C. Specific Examples of Anticancer Imidazolidine-2,4-dione Derivatives

Several hydantoin derivatives have been identified with promising anticancer activities. For example, 5,5-diphenylhydantoin (phenytoin) has shown efficacy against various cancer cell lines by inducing apoptosis and inhibiting cell proliferation. Another example is 3,5-dimethyl-2,4-dioxoimidazolidine, which has demonstrated significant activity against breast cancer cells by disrupting cellular signalling pathways (Singh et. al. 2006 & Cho et al., 2019).

D. Comparative Analysis with Existing Anticancer Drugs

When compared to existing anticancer drugs, hydantoin derivatives offer several advantages. They often exhibit lower toxicity and fewer side effects, making them more tolerable for patients. Additionally, the structural flexibility of hydantoins allows for the development of derivatives that can overcome resistance mechanisms commonly encountered with traditional chemotherapy drugs. Studies have shown that hydantoins can be as effective as, if not more than, conventional anticancer agents such as doxorubicin and cisplatin, particularly in targeting resistant cancer cell lines (Cho et al., 2019).

V. Structure-Activity Relationships (SAR)

A. Importance of SAR in Medicinal Chemistry

Structure-activity relationship (SAR) studies are fundamental in medicinal chemistry as they provide critical insights into how the chemical structure of a molecule affects its biological activity. By understanding SAR, chemists can design more potent and selective drugs with improved efficacy and reduced side effects. SAR analysis involves systematic modifications of chemical structures and evaluation of their impact on biological activity, which helps identify key structural features necessary for optimal interaction with biological targets (Mahajan et al., 2022).

B. Key Structural Features Influencing Biological Activity

The biological activity of imidazolidine-2,4-dione derivatives is influenced by several key structural features:

Substituent Groups: The nature and position of substituents on the hydantoin ring significantly impact their biological activity. For example, electron-donating groups often enhance antimicrobial and anticancer properties, while electron-withdrawing groups might reduce activity (Yin et al., 2022).

Ring Modifications: Variations in the imidazolidine ring, such as the introduction of additional rings or heteroatoms, can alter the **Antimicrobial Activity**: In a study by Mahajan et al. (2022), modifications on the hydantoin ring, such as the addition of benzyl or phenyl groups, enhanced antibacterial activity against both Gram-positive and Gram-negative bacteria. For example, N-benzyl-substituted hydantoins showed superior activity due to increased hydrophobic interactions with bacterial cell membranes.

Anticancer Activity: Research by Kumar et al. (2019) demonstrated that hydantoin derivatives with bulky aromatic substituents exhibited potent anticancer activity. These modifications improved the compounds' ability to induce apoptosis and inhibit cell proliferation in cancer cells. Structural optimization led to derivatives with higher selectivity for cancer cells over normal cells.

D. Implications for Future Drug Design

The insights gained from SAR studies of imidazolidine-2,4-dione derivatives have significant implications for future drug design. Understanding the relationship between structure and activity allows for the rational design of new derivatives with enhanced therapeutic profiles. Future drug development can focus on:

Targeted Modifications: Using SAR knowledge to introduce specific functional groups that enhance target specificity and reduce off-target effects.

Optimized Pharmacokinetics: Designing derivatives with improved solubility, stability, and bioavailability by balancing hydrophobic and hydrophilic properties.

Reduced Toxicity: Identifying structural features that minimize toxicity while maintaining or enhancing therapeutic efficacy.

By leveraging SAR insights, medicinal chemists can develop more effective and safer drugs for treating various diseases (Mahajan et al. 2022 & Cho et al., 2019).

VI. Therapeutic Potential and Clinical Applications

A. Preclinical Research Findings: Preclinical research on imidazolidine-2,4-dione derivatives, commonly known as hydantoins, has revealed their potential as therapeutic agents. These compounds have demonstrated significant efficacy in various disease models, particularly in antimicrobial and anticancer settings. For instance, preclinical studies have shown that hydantoin derivatives can effectively inhibit the growth of resistant bacterial strains and induce apoptosis in cancer cells (AbdulJabar et al., 2021; Rahman et al., 2024).

B. Potential Clinical Applications and Advantages: Antimicrobial Agents: Hydantoin derivatives have shown promise as broad-spectrum antimicrobial agents. Their ability to target both Gram-positive and Gram-negative bacteria, as well as fungal pathogens, positions them as potential alternatives to existing antibiotics, particularly in the face of rising antimicrobial resistance (Zhou et al., 2020).

Anticancer Therapies: Hydantoin derivatives exhibit potent anticancer properties, with mechanisms involving the induction of apoptosis and inhibition of cell proliferation. These compounds could be developed as chemotherapeutic agents, offering advantages such as lower toxicity and higher specificity compared to traditional drugs like cisplatin (Gawas et al., 2021). **Antiviral Agents**: Preliminary studies suggest that hydantoins may also have antiviral properties, which could be harnessed in the treatment of viral infections like herpes simplex virus (HSV) and human immunodeficiency virus (HIV). Their ability to inhibit viral replication could make them valuable in antiviral therapy (Rajjic et al., 2006 & Scully et al. 1998).

C. Safety and Toxicity Considerations While hydantoins have shown therapeutic potential, safety and toxicity considerations are crucial for their clinical development. Preclinical toxicity studies have indicated that certain hydantoin derivatives exhibit low toxicity profiles, making them suitable for further development. However, it is essential to conduct comprehensive compound's binding affinity and specificity towards its biological target. These modifications can improve pharmacokinetic properties and reduce toxicity (Rani et al., 2020).

Hydrophobicity/Hydrophilicity: The balance between hydrophobic and hydrophilic moieties in the molecule affects its solubility, permeability, and overall bioavailability. Hydantoin derivatives with optimal hydrophobic/hydrophilic balance tend to exhibit better biological activity (Cho et al., 2019).

C. Case Studies of SAR in Imidazolidine-2,4-dione Derivatives

toxicity assessments, including acute and chronic toxicity studies, to ensure their safety in humans (Gawas, 2021 & Cho et al., 2019).

Cytotoxicity: Evaluations of cytotoxicity against normal cell lines are necessary to ensure selective toxicity towards cancer cells.

Hepatotoxicity and Nephrotoxicity: Potential effects on liver and kidney functions should be closely monitored.

Genotoxicity: Assessments to determine if hydantoins cause genetic mutations or chromosomal damage are crucial for long-term safety.

D. Future Directions for Clinical Research The promising preclinical findings and potential clinical applications of hydantoin derivatives pave the way for future research. Key areas of focus should include:

Clinical Trials: Initiating phase I and II clinical trials to evaluate the safety, tolerability, and efficacy of hydantoin derivatives in humans.

Mechanistic Studies: Conducting detailed studies to elucidate the precise mechanisms of action, which can help in optimizing their therapeutic potential.

Combination Therapies: Exploring the use of hydantoin derivatives in combination with existing therapies to enhance therapeutic outcomes and overcome resistance.

Formulation Development: Developing formulations that improve the bioavailability and stability of hydantoin derivatives, ensuring optimal delivery to target sites.

CONCLUSION

A. Summary of Main Findings: This review has highlighted the diverse biological activities of imidazolidine-2,4-dione derivatives, emphasizing their potential as antimicrobial and anticancer agents. These compounds have shown significant efficacy against a broad spectrum of bacterial, fungal, and viral pathogens, as well as various cancer cell lines. Mechanistic studies have revealed that their biological activities are primarily mediated through the induction of apoptosis, inhibition of cell proliferation, and disruption of critical cellular signalling pathways. Structural-activity relationship (SAR) analyses have identified key structural features that influence their biological activity, providing valuable insights for the design of more potent and selective derivatives.

B. Implications for Future Research and Drug Development The promising preclinical findings on imidazolidine-2,4-dione derivatives suggest several avenues for future research and drug development. Conducting rigorous clinical trials will be crucial to evaluate the safety, efficacy, and pharmacokinetic properties of these compounds in humans. Further mechanistic studies are needed to fully elucidate the pathways involved in their antimicrobial and anticancer activities. Additionally, exploring combination therapies with existing drugs may enhance therapeutic outcomes and mitigate resistance. Continued SAR studies will help in the rational design of new derivatives with improved therapeutic profiles and reduced toxicity.

C. Final Thoughts on the Therapeutic Potential of Imidazolidine-2,4-dione Derivatives The therapeutic potential of imidazolidine-2,4-dione derivatives is substantial, offering a promising avenue for the development of new antimicrobial and anticancer agents. Their broad-spectrum activity, coupled with favourable safety profiles, positions them as valuable candidates for further development. By leveraging the insights gained from SAR studies and preclinical research, these compounds can be optimized to address current challenges in treating infectious diseases and cancer. Overall, imidazolidine-2,4-dione derivatives represent a versatile and potent class of compounds with significant potential to contribute to future therapeutic strategies.

REFERENCES

- AbdulJabar, L. A., Mutalq, D. Z., & Al-Shawi, A. A. (2021). Sythesis Of Novel 2-Thioxo-4-Imidazolidinone Derivatives And Evaluate Their Antibacterial, And Antifungal Activities. *Egyptian Journal of Chemistry*, *64*(6), 3059-3067.
- Ali, D., Alarifi, S., Chidambaram, S. K., Radhakrishnan, S. K., & Akbar, I. (2020). Antimicrobial activity of novel 5-benzylidene-3-(3-phenylallylideneamino) imidazolidine-2, 4-dione derivatives causing clinical pathogens: Synthesis and molecular docking studies. *Journal of Infection and Public Health*, *13*(12), 1951-1960.
- Balabon, O., Pitta, E., Rogacki, M. K., Meiler, E., Casanueva, R., Guijarro, L., ... & Van der Veken, P. (2020). Optimization of hydantoins as potent antimycobacterial decaprenylphosphoryl-ß-d-ribose oxidase (DprE1) inhibitors. *Journal of Medicinal Chemistry*, *63*(10), 5367-5386.
- Bhadresh R. Sudani and Vikas A. Desai (2015). An Overview about Medicinal Chemistry and Pharmaceutical Applications of 2, 4-Imidazolidinone and its Derivatives. *Asian Journal of Pharmacy and Technology*, *5*(3), 153-157.
- Bhattacharjee, M. K. (2022). Antibiotics that inhibit nucleic acid synthesis. In *Chemistry of antibiotics and related drugs* (pp. 125-148). Cham: Springer International Publishing.
- Borisa, A. C., Bhatt, H. G., Thakkar, D., & Trivedi, S. (2015). ISO-STERIC REPLACEMENT OF THIAZOLIDIENE DIONE TO IMIDAZOLINE DIONE (HYDANTOIN) AS A NOVEL SCAFFOLD: SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF PTP1B INHIBITORS. *World Journal of Pharmacy and Pharmaceutical Sciences*, *4*(4), 928-941.
- Cho, S., Kim, S. H., & Shin, D. (2019). Recent applications of hydantoin and thiohydantoin in medicinal chemistry. *European journal of medicinal chemistry*, *164*, 517-545.
- Gawas, P. P., Ramakrishna, B., Veeraiah, N., & Nutalapati, V. (2021). Multifunctional hydantoins: Recent advances in optoelectronics and medicinal drugs from Academia to the chemical industry. *Journal of Materials Chemistry C*, *9*(46), 16341-16377.
- Kavitha, C. V., Nambiar, M., Kumar, C. A., Choudhary, B., Muniyappa, K., Rangappa, K. S., & Raghavan, S. C. (2009). Novel derivatives of spirohydantoin induce growth inhibition followed by apoptosis in leukemia cells. *Biochemical pharmacology*, *77*(3), 348-363.
- Kumar, C. A., Swamy, S. N., Sugahara, K., & Rangappa, K. S. (2009). Anti-tumor and anti-angiogenic activity of novel hydantoin derivatives: Inhibition of VEGF secretion in liver metastatic osteosarcoma cells. *Bioorganic & medicinal chemistry*, *17*(14), 4928-4934.
- Mahajan, A., Singh, H., Singh, A., Agrawal, D. K., Arora, A., & Chundawat, T. S. (2022). Trifluoromethylated Quinolone-Hydantoin Hybrids: Synthesis and Antibacterial Evaluation. Sci 2022, 4, 30.
- Marques, C. S., Carreiro, E. P., & Teixeira, A. P. (2022). Multicomponent Synthesis of Heterocycles. *Heterocycles: Synthesis, Catalysis, Sustainability, and Characterization*, 215-275.
- Mondino, M. G., & da Silva Gomes, R. (2022). Imidazole, Hydantoins, Thiazole, and Oxazole: A Journey on Synthetic and Biological Relevance. In *N-Heterocycles: Synthesis and Biological Evaluation* (pp. 51-95). Singapore: Springer Nature Singapore.
- Mousavi, S. M., Zarei, M., Hashemi, S. A., Babapoor, A., & Amani, A. M. (2019). A conceptual review of rhodanine: current applications of antiviral drugs, anticancer and antimicrobial activities. *Artificial cells, nanomedicine, and biotechnology*, *47*(1), 1132-1148.
- Nyaki, H. Y., Mahmoodi, N. O., Nahzomi, H. T., & Kokhdan, E. P. (2023). Two-and Three-Directional Synthesis by 3-7MCRs of Novel (Imidazolidine/Thiazolidine)-2, 4-Diones: Characterization, Antibacterial, Anticonvulsant and Molecular Docking Investigation.
- Rahman, A. (2024). Bioactivity profiling and mode of action studies of antibacterial and antibiofilm agents of marine origin.
- Scully, C., Monteil, R., & Sposto, M. R. (1998). Infectious and tropical diseases affecting the human mouth. *Periodontology 2000*, *18*(1), 47-70.
- Sevvanthi, S., Muthu, S., & Raja, M. (2017). Quantum mechanical, spectroscopic studies and molecular docking analysis on 5, 5-diphenylimidazolidine-2, 4-dione. *Journal of Molecular Structure*, *1149*, 487-498.
- Singh, G., Driever, P. H., & Sander, J. W. (2005). Cancer risk in people with epilepsy: the role of antiepileptic drugs. *Brain*, *128*(1), 7-17.
- Sharma, B., Singh, V. J., & Chawla, P. A. (2021). Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress. *Bioorganic Chemistry*, *116*, 105393.
- Su, M., Xia, D., Teng, P., Nimmagadda, A., Zhang, C., Odom, T., ... & Cai, J. (2017). Membrane-active hydantoin derivatives as antibiotic agents. *Journal of medicinal chemistry*, *60*(20), 8456-8465.
- Sudani, B. R., & Desai, V. A. (2019). Synthesis, characterization and biological activity of some glycolylurea and ß-lactam merged heterocyclic compounds. *Asian Journal of Pharmacy and Pharmacology*, *5*(3), 460-463.
- Sunil, D., & Kamath, P. R. (2017). Multi-target directed indole based hybrid molecules in cancer therapy: an up-to-date evidence-based review. *Current topics in medicinal chemistry*, *17*(9), 959-985.
- Swain, S. P., & Mohanty, S. (2019). Imidazolidinones and Imidazolidine-2, 4-diones as Antiviral Agents. *ChemMedChem*, *14*(3), 291-302.
- Rajic, Z., Zorc, B., Raic-Malic, S., Ester, K., Kralj, M., Pavelic, K., ... & Mintas, M. (2006). Hydantoin derivatives of L-and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. *Molecules*, *11*(11), 837-848.
- Rani, N., Kumar, P., Singh, R., de Sousa, D. P., & Sharma, P. (2020). Current and future prospective of a versatile moiety: imidazole. *Current Drug Targets*, *21*(11), 1130-1155.
- Toumi, A., Abdella, F. I., Boudriga, S., Alanazi, T. Y., Alshamari, A. K., Alrashdi, A. A., ... & Strohmann, C. (2023). Synthesis of tetracyclic spirooxindolepyrrolidine-engrafted hydantoin scaffolds: crystallographic analysis, molecular docking studies and evaluation of their antimicrobial, anti-inflammatory and analgesic activities. *Molecules*, *28*(21), 7443.
- V Krivoshein, A. (2016). Antiepileptic drugs based on the α-substituted amide group pharmacophore: From chemical crystallography to molecular pharmaceutics. *Current Pharmaceutical Design*, *22*(32), 5029-5040.
- Upadhyay, N., Tilekar, K., Loiodice, F., Anisimova, N. Y., Spirina, T. S., Sokolova, D. V., ... & Ramaa, C. S. (2021). Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. *Bioorganic Chemistry*, *107*, 104527.
- Yin, L. J., bin Ahmad Kamar, A. K. D., Fung, G. T., Liang, C. T., & Avupati, V. R. (2022). Review of anticancer potentials and structure-activity relationships (SAR) of rhodanine derivatives. *Biomedicine & Pharmacotherapy*, *145*, 112406.
- Zhou, M., Zheng, M., & Cai, J. (2020). Small molecules with membrane-active antibacterial activity. *ACS applied materials & interfaces*, *12*(19), 21292-21299.